ttc-352
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 11, 2017 (NCT03201913)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Estrogen receptorAGONIST
Estrogen receptor agonist
Chemistry & pharmacology
Loading structure…
SMILES
Oc1ccc(Oc2sc3cc(O)ccc3c2-c2ccc(F)cc2)cc1- Mol. weight
- 352.39 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3763743 ↗
Also known as
- ttc-352
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03201913 | Phase 1 | Dec 11, 2017 | TTC Oncology, LLC |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TTC Oncology, LLC | For profit | 1 | 1 | 1 | 2017 |
1 organizations
Page 1 / 1